Abstract
ObjectiveThis study aimed to investigate the biological role of C5orf34 in Lung adenocarcinoma (LAD) and the mechanism of such role. MethodsThe mRNA expression of C5orf34 was analyzed using student's t-test based on the data obtained from TCGA database. Kaplan-Meier analysis was performed to evaluate the prognosis value of C5orf34. Chi-square (χ2) test was performed to analyze the correlation between C5orf34 expression and clinical features. The effect of C5orf34 siRNA on A549 and SPCA1 cells proliferation and migration were explored using CCK8 assay, wound healing assay and transwell assays, respectively. Western blot was performed to evaluate the expression of C5orf34, ERK, p-ERK, MEK and p-MEK. ResultsC5orf34 expression was enhanced in LAD and positively correlated with poor prognosis in patients with LAD. χ2 test revealed that C5orf34 expression was obviously associated with age (p = 0.016), Pathologic-Stage (p = 0.045) and Pathologic-N (p = 0.023). In addition, knockdown of C5orf34 significantly suppressed A549 and SPCA1 cells proliferation and motility (p < 0.01) in vitro. Moreover, by western blot analysis, we found that depleting C5orf34 remarkably reduced the ratio of p-MEK/MEK and p-ERK/ERK in A549 cells. ConclusionOur results firstly revealed that C5orf34 might play a facilitating role in LAD development and progression by regulating MAPK signaling pathway. Furthermore, our data implied that C5orf34 may be a potential predictor and treatment target for LAD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
